Cargando…
The impact of specific cytokine directed treatment on severe COVID-19
Autores principales: | Reuken, P. A., Rüthrich, M. M., Hochhaus, A., Hammersen, J., Bauer, M., La Rosée, P., La Rosée, F., Stallmach, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422045/ https://www.ncbi.nlm.nih.gov/pubmed/34493799 http://dx.doi.org/10.1038/s41375-021-01411-1 |
Ejemplares similares
-
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
por: Hammersen, J., et al.
Publicado: (2023) -
P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
por: Birndt, Sebastian, et al.
Publicado: (2023) -
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
por: La Rosée, F., et al.
Publicado: (2020) -
Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation
por: La Rosée, P., et al.
Publicado: (2020) -
Erratum zu: Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter Hyperferritinämischer Inflammation
por: La Rosée, P., et al.
Publicado: (2020)